Intended for healthcare professionals


Findings from COX 2 studies are released

BMJ 2005; 330 doi: (Published 17 February 2005) Cite this as: BMJ 2005;330:381
  1. Scott Gottlieb
  1. New York

    Results from recent studies that raised concerns about the cardiovascular safety of cyclo-oxygenase-2 (COX 2) inhibitors have been made available early, in advance of hearings on the drug class by the US Food and Drug Administration.

    All the studies have been published online in the New England Journal of Medicine (, and the journal lifted its normal embargo date for the studies because of what it described as the “possible public health implications.”

    The results come immediately before a three-day hearing looking into the benefits and risks of COX 2 inhibitors …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription